EBV-induced immortalization of primary human B cells leads to the outgrowth of lymphoblastoid cell lines (LCLs) which display a latency III pattern, characterized by the expression of all nine viral latent gene products. These include the nuclear antigens EBNA1, -2, -3a, -3b, and -3c, the leader protein EBNA4, and latent membrane protein 1 (LMP1), LMP2A, and LMP2B (reviewed in reference 18). Often, BL
The use of different viral promoters for the expression of the EBNA1 gene product appears to be a critical step in the regulation of Epstein-Barr virus latent gene expression and may reflect the extent of differentiation of B-cell hosts. Low-passage Burkitt lymphoma cell lines resemble immature B cells in that they express CD10 (CALLA) and do not express B-cell activation antigens. In these cells, transcription from a promoter located in the BamHI F fragment of the viral genome results in the exclusive expression of EBNA1, referred to as the latency I pattern of viral gene expression. In contrast, high-passage Burkitt lymphoma cells and lymphoblastoid cell lines resemble activated B cells in that they do not express CD10 but do express activation antigens such as CD23. In these cells, the use of two promoters located in the BamHI W and C fragments of the viral genome leads to the expression of all six EBNA gene products (latency III). We have found that four human B-cell lines, DB, .LBW2, LBW14, and Josh 7, stably express a pattern of B-cell differentiation antigens intermediate between those found in latency I and latency Ill cell lines and characterized by the coexpression of CD10 and CD23. The pattern of EBNA1 promoter usage in these cell lines was examined to determine whether their intermediate cellular phenotype was reflected in their patterns of viral gene expression. DB, LBW2, and LBW14 utilize both the BamHI F promoter region and BamHI W promoter region to transcribe the EBNA1 gene..This stable pattern of mixed promoter usage for the expression of the EBNA gene products in B cells has not previously been described. In addition, these three B-cell lines expressed lower levels of the viral latent gene product EBNA2 than those typically observed in latency III cells. The lower levels of activation of viral and cellular promoters known to be regulated by EBNA2 also correlated with the reduced levels of EBNA2 expression in these cells. These included the viral LMP1 and LMP2A promoters and the cellular CD23B promoter. Thefourth B-cell line, Josh 7, expressed EBNA1 mRNAs derived from both the BamHI W promoter and BamHI C promoter, similar to latency III cells. The intermediate cellular phenotype in Josh 7 cells appeared to be due, in part, to a deficiency in the expression of viral LMP1. These results show that the B-cell lines express unique intermediate patterns of expression of viral and cellular gene products and suggest that a continuum of latency states may exist for Epstein-Barr virus-infected B lymphocytes.
The ability of Epstein-Barr virus (EBV) to immortalize primary human B lymphocytes and its strong association with several human malignancies have stimulated intensive study on the nature of the EBV-host cell interaction. Two patterns of latent EBV infection in human B cells which reflect differences in both the pattern of viral gene expression and the B-cell phenotype have been described. Freshly isolated EBV-positive Burkitt lymphoma (BL) tumors express surface markers, such as CD10, that are typical of immature B cells. In culture, these tumor cells are generally spherical and grow as a single cell carpet. These cells express a single viral nuclear antigen, EBNA1, which typifies the latency I pattern of viral gene expression.
EBV-induced immortalization of primary human B cells leads to the outgrowth of lymphoblastoid cell lines (LCLs) which display a latency III pattern, characterized by the expression of all nine viral latent gene products. These include the nuclear antigens EBNA1, -2, -3a, -3b, and -3c, the leader protein EBNA4, and latent membrane protein 1 (LMP1), LMP2A, and LMP2B (reviewed in reference 18) . Often, BL cell lines evolve to a latency III pattern of gene expression during passage in culture (37) . Viral latent gene expression induces changes in B-cell phenotype which are consistent with the phenotype of activated B cells. Specifically, EBNA2 and LMP1 act to upregulate B-cell activation antigens, such as CD23, and cellular adhesion molecules, like ICAM-1 and LFA-1 (48, 51) . Furthermore, the expression of CD10 is significantly downregulated (51) . Unlike BL cell lines, LCLs are usually pleiomorphic and generally grow in large clumps rather than single-cell suspensions.
EBV exhibits a dual cellular tropism, infecting epithelial cells in addition to lymphoid cells. EBV-infected epithelial cells, epitomized by nasopharyngeal carcinoma (NPC) tumor cells, display a pattern of viral gene expression designated latency II. This is characterized by the restricted expression of EBNA1 in the absence of EBNA2 to -4 and the variable expression of LMP1 and LMP2 (2) .
A key point in the regulation of viral latent gene products appears to be the promoter used in transcription of the EBNA1 gene. In latency I BL cell lines and latency II NPC cell lines, EBNA1 gene transcription occurs from a promoter located in the BamHI F fragment of the viral genome. The activation of this promoter alone leads to the exclusive expression of EBNA1 (38, 44 Determined by Northern analysis.
fragments results in the expression of EBNA1 to -4 through differential splicing (45) . The activities of the W and C promoters are often mutually exclusive (55) . Transcription from the W promoter, utilized during the initial stages of EBV infection of primary B cells, is downregulated in most established LCLs in favor of the dominant C promoter (56) . EBNA2 has been strongly implicated in the activation of the C promoter (34, 47, 54 (12, 13) . DB was generated under identical conditions with PBLs from a healthy individual (13 (35) . Radiolabeled probes were generated by random primed second-strand synthesis (6 (Fig. 1A) . EBNA2-negative Daudi cells (Fig. 1B) . The expression of CD23 in the round B-cell lines, however, is intermediate between that of LCLs and that of BJAB or Daudi cells.
The levels of expression of the cellular adhesion molecules ICAM-1 and LFA-1, as well as the level of homotypic adhesion, are often increased following EBV infection of B cells (51) . Figure 1C shows that the round B-cell lines expressed levels of ICAM-1 comparable to those observed for the BJAB and Daudi cell lines. The LCL LBW4 expressed typically high levels of ICAM-1, whereas the LBW26 cell line is somewhat unusual in that it expressed only low levels of this adhesion molecule. Figure 1D shows the results obtained for the expression of LFA-1. As in the case of ICAM-1, the round B-cell lines expressed levels of LFA-1 similar to the levels expressed in the BJAB (37) . In that case, some cells may express CD10 alone while others express CD23 solely. To address this possibility, the round B-cell lines were analyzed by double-label immunofluorescence for coexpression of CD10 and CD23. In addition, the round B-cell line LBW14 was subcloned and two separate subclones were selected and analyzed for coexpression of CD10 and CD23. Figure 2A and B show that the DB and LBW14 round B-cell populations consistently coexpress the B-cell markers CD10 and CD23. All CD23-positive cells also express CD10. Analysis of the round B-cell lines LBW2 and Josh 7 also showed a similar pattern of coexpression of these cell markers (data not shown). Figure 2C and D show that there was no difference in the pattern of expression of CD10 and CD23 by the two subclones of LBW14 compared with that of the parental cell line, indicating that the expression of these markers is not due to phenotypic drift in the population.
Promoter ,,, promoter located in the BamHI F fragment of the viral genome. The activation of this promoter alone leads to the exclusive expression of EBNA1 (38) . In contrast, in LCLs and latency III BLs, transcription from promoters located within the BamHI W fragment or C fragment of the viral genome results in the expression of EBNA1 to -4 through differential splicing (45) .
Poly(A)+ RNAs from the four round B-cell lines were analyzed for the presence of EBNA1 transcripts by reverse transcription and PCR amplification with a 3' primer derived from the EBNA1 coding region (16) . EBNA1 transcripts originating from the C/W promoter region were amplified with a 5' primer sequence which hybridizes to the BamHI Y3 exon and generates an amplification product of 265 bp. Transcripts expressed from the F promoter were amplified with a primer sequence from the BamHI Q exon which gives rise to a 236-bp amplification product (16) . As seen in Fig. 3 , DB, LBW2, and LBW14 cell lines generate EBNA1 transcripts from both the F and C/W promoter regions, with F usage clearly predominating in DB and LBW2 samples. Utilization of both of these promoter regions has been observed previously only as a transient feature of B-cell hosts infected with EBV (16, 20, 36) . The BL cell line Daudi also expressed a transcript derived from the F promoter. However, an amplification product is not generated by the Y3 exon primer since this cell line contains a deletion in the EBNA2 coding region which encompasses the Y3 exon (15) . While the growth characteristics and surface marker expression of the Josh 7 cell line are similar to those of the other round B-cell lines, it differs by utilizing the C/W promoter region for the transcription of the EBNA gene products, with markedly reduced usage of the F promoter. This is comparable to the pattern of promoter usage seen in the control LCLs LBW25 and LBW26.
Because the round B-cell lines produce EBNA1 transcripts that include the Y3 region, a separate experiment was done to distinguish between transcripts derived from the W promoter and those derived from the C promoter (Fig. 4) . Transcripts expressed from the W promoter were amplified with a 5' primer sequence from the WO exon which gives rise to a 210-bp amplification product (16) . Transcripts generated from the C promoter were detected with a 5' primer sequence which hybridizes to the Cl exon and amplifies a 240-bp product (16) . Reverse transcription and amplification of poly(A)+ RNAs from DB, LBW2, and LBW14 cells gave low but detectable amounts of PCR products from W promoter-derived transcripts. The Josh 7 cell line utilized the W promoter to a degree similar to that of the LCL controls (Fig. 4) . C promoterderived transcripts were also detected in the Josh 7 cell line and the LCLs LBW25 and LBW26. However, even after extensive autoradiographic exposure, no C promoter-specific PCR products were seen with RNAs from the DB, LBW2, or LBW14 cell line. The Daudi cell line did not yield detectable C promoter-derived transcripts but did express transcripts derived from the W promoter, as described previously (55) . These transcripts were not detected in the experiment shown in Fig. 3 because of the deletion of the Y3 primer sequence explained above. Thus, the Daudi cell line resembles the round B-cell lines in its use of both the F and W promoters, although the results in Fig. 4 (20) . The use of the F promoter in the DB, LBW2, and LBW14 cell samples, therefore, could be due to the presence of a subpopulation of cells which are undergoing a lytic EBV infection. To address this possibility, the round B-cell lines were examined for the expression of BZLF1 transcripts, a viral transcription factor involved in the activation of the lytic cycle (27, 35) . Figure 5A shows that BZLF1 mRNA was only marginally detectable in the four round B-cell lines. Furthermore, this level of BZLF1 expression was considerably lower than the levels observed in the typical LCLs LBW26 and GM02292, which do not show any F promoter activity ( Fig. 3 and data not shown) . In order to provide further evidence that the F promoter expression observed in the round B-cell lines was not due to spontaneous entry into the lytic cycle, a separate PCR experiment (20) was done to analyze the expression of the spliced 1.7-kb BHRF1 mRNA, an abundant immediate-early lyticcycle transcript (28) . Poly(A)+ RNA was reverse transcribed and then amplified with primers specific for the BamHI H3 and BamHI H2 exons, respectively. A 213-bp product specific for this transcript was detected on a Southern blot with a radiolabeled BamHI H cDNA probe. Figure SB shows that the round B-cell lines LBW14, LBW2 and Josh 7 express little, if any, of this BHRF1 transcript. The DB cell line expresses BHRF1 transcripts at a level similar to those of the LCLs LBW26 and GM02292. Consistent with the data obtained for the expression of BZLF1 (Fig. 5A) (Fig. 7A) . The round B-cell lines DB, LBW2, LBW14, and Josh 7 expressed EBNA2 transcripts at far lower steady-state levels than did the LBW25 and LBW26 LCL controls. In addition, the EBNA2-hybridizing transcript was 3.0 kb. This is smaller than the EBNA2 mRNAs expressed in the LBW25 and LBW26 LCLs. This variation in EBNA2 mRNA size between B-cell lines, even between those infected with the same virus stock, has precedents and is due to a structural polymorphism in the repeated BamHI W region of EBV genomes (5) . Analysis of the levels of 1-actin mRNA indicated that approximately equal amounts of RNA were loaded into all lanes.
The expression of EBNA2 protein in the round B-cell lines was examined by Western blots in which cellular lysates were probed with the PE2 monoclonal antibody to the EBNA2 protein (Fig. 7B) . The round B-cell lines DB, LBW2, LBW14, and Josh 7 expressed an EBNA2 protein with the same apparent molecular mass (82 kDa) as that expressed by the LBW25 and LBW26 LCL controls. This indicates that the differences in the sizes of the EBNA2 mRNAs (Fig. 7A) are not due to differences in the size of the EBNA2 coding region. The round B-cell lines expressed approximately three-to fourfold less EBNA2 protein than did the LBW25 and LBW26 LCL controls, with the exception of the Josh 7 cell line, which expressed EBNA2 protein at somewhat higher levels. The quantitative differences between the round B-cell lines and LCLs were confirmed by analyzing serial dilutions of cell extracts by Western blots (data not shown). These results were consistent with the lower levels of EBNA2 transcripts observed in the round B-cell lines. However, the differences between the round B-cell lines and LCLs were more striking when EBNA2 mRNA (Fig. 7A ) rather than the differences in EBNA2 protein expression (Fig. 7B) was analyzed.
Expression of viral and cellular genes coregulated by EBNA2. EBNA2 has been shown to play a role in upregulating the expression of several viral and cellular genes. Since the round B-cell lines express lower levels of EBNA2 protein than typical LCLs, the effects of this low level of expression on other EBNA2-responsive genes were investigated. EBNA2 upregulates the expression of the viral LMP1 and LMP2 (49, 53, 58) . Therefore, poly(A)+ mRNAs from the round B-cell lines were assayed for the presence of LMP1 by Northern analysis. Figure  8A shows that the cell lines LBW14, LBW2, and DB express LMP1 transcripts, though at somewhat lower levels than the LCL LBW4. LMP1 mRNA was present in much smaller amounts in Josh 7 cells than in the other round B-cell lines and was observed in Josh 7 samples only upon a fivefold-longer autoradiographic exposure. The 2.6-kb LMP1 transcript seen in the round B-cell lines was the expected size for B-cell hosts (39) . However, a 3.7-kb LMP1 transcript expressed in NPC tumors and in some LCLs was not observed in any of the B-cell lines tested (11) .
By Western blot (Fig. 8B) with the anti-LMP1 monoclonal antibody S12 (23), a 56-kDa LMP1 protein was readily detected in the LBW14, LBW2, and DB cell lines while little or no LMP1 protein was detected in the Josh 7 cell line. A significantly higher level of LMP1 protein was detected in the LCL LBW4. This result is consistent with the levels of LMP1 mRNA expressed in the round B-cell lines and suggests that The LMP2 gene lies across the terminal regions of the viral genome, and two distinct LMP2 mRNAs can be generated. LMP2A and LMP2B mRNAs have differing 5' exons because of the use of different promoters, with subsequent alternative splicing of the unique 5' exon to the common exons 2 to 9 in the primary transcript (19, 40) . To determine if the round B-cell lines express normally initiated LMP2A or LMP2B transcripts, a separate PCR experiment with primers specific to the 5' exon unique to each message was carried out (16) . Figure 9 shows apparently normally initiated LMP2B transcripts in the round B-cell lines DB, LBW2, LBW14, and Josh 7, but little or no mRNA containing the LMP2A 5' exon could be detected. As expected, transcripts of both LMP2A and LMP2B were expressed in the LCL control samples LBW25 and LBW26. In contrast to the round B-cell lines, the EBNA2-deficient cell line Daudi expressed LMP2A transcripts but not LMP2B transcripts.
The EBV latent gene products EBNA2 and LMP1 induce the expression of the B-cell activation antigen CD23 (51, 52) . Two species of CD23 mRNA, types A and B, which utilize different promoters and include unique 5' exons have been described. Type A is expressed in all B cells, whereas type B is expressed only in response to activating signals (57) . EBNA2 and LMP1 induce the expression of type B CD23 mRNA and also increase the expression of constitutive type A mRNA (51) . Since the round B-cell lines express intermediate levels of CD23, a PCR experiment was performed to distinguish the expression of CD23A from that of virally induced CD23B ( Amplification products were separated on an agarose gel, blotted onto a nylon membrane, and probed with an internal oligonucleotide capable of hybridizing to both products. Transcripts originating from the LMP2A promoter give rise to a PCR product of 280 bp, whereas transcripts from the LMP2B promoter give a product of 324 bp, as indicated. The EBNA2-negative cell line Daudi and the LCLs LBW25 and LBW26 were included as controls.
analyzed for the presence of CD23A and CD23B transcripts by reverse transcription with a 3' primer sequence common to both transcripts and then by amplification with 5' primer sequences unique to each CD23 transcript. The type A amplification product is 320 bp, whereas the type B product is 316 bp. Figure 10 shows that only constitutive type A CD23, and not inducible type B, was detected in the round B-cell lines. Both forms of CD23 transcripts were detected in LCLs, as expected. This result is consistent with the lower levels of total CD23 on the surfaces of the round B-cell lines and the lower levels of EBNA2 and LMP1 compared with those of the LCL controls (Fig. 1, 5 , and 6).
DISCUSSION
An important step in the regulation of EBV latent gene expression is the use of either the F promoter or the C/W promoter region to express EBNA1 (38, 56) . The promoter used for EBNA1 expression determines whether only EBNA1 or all six EBNA genes are expressed. The round B-cell lines DB, LBW2, and LBW14 are unique among previously described B-cell systems in that they utilize both of these promoter regions to transcribe the EBNA1 gene ( Fig. 2 and 3) . NPC cell lines occurs exclusively from the F promoter (38, 44 ). Yet, unlike latency I or latency II cell lines, the round B-cell lines show activation of the F promoter as well as limited use of the W promoter. The W promoter is typically used during the early stages of EBV infection of primary B cells prior to switching to the C promoter (56) .
The apparent lack of transcripts derived from the C promoter in the DB, LBW2, and LBW14 round B-cell lines implies that they have failed to switch to the C promoter for the expression of the EBNA genes as is normally seen in latent infections of LCLs. Alternatively, it is possible that viral C promoters in the round B-cell lines are not capable of being activated as a result of mutation. This is not likely to be the case, however, since preliminary evidence indicates that the C promoters in the round B-cell lines can be used in response to activating signals (unpublished data). The use of dual promoters in the DB, LBW2, and LBW14 cell lines is accompanied by a pattern of coexpression of the cellular differentiation antigens CD1O and CD23 that is intermediate between those of latency I and latency III B-cell lines ( Fig. 1 and 2 ). Transient dual expression of F and C/W transcripts has been observed previously in the evolution of latency I BL cells and LCLs to a latency III phenotype during passage in culture and in latency III LCLs switching to the lytic cycle (16, 20, 36) . Similarly, transient coexpression of CD10 and CD23 has been observed during the evolution of BL cell lines in culture (37 (Fig. 6) . Thus, the cellular phenotype of the Josh 7 cell line may result from an absence of viral or cellular factors necessary for LMP1 expression.
The BL cell line Daudi is similar to the DB, LBW2, and LBW14 round B-cell lines both in cellular phenotype and in viral promoter usage (Fig. 1, 2, and 3 ). As shown, Daudi cells utilize both the F and W promoters for the transcription of the EBNA genes ( Fig. 2 and 3) , although the transcription from the W promoter is much more pronounced in Daudi cells than in the round B-cell lines (Fig. 3) . The transcription from the W promoter in Daudi cells has been previously described (55) . The deletion of the region of the viral genome encoding the EBNA2 gene in Daudi cells (15) prevents the EBNA2-dependent switch to the C promoter (56) . In contrast to Daudi cells, the deletion of the EBNA2 coding region was not detected in the round B-cell lines (Fig. 4) . Additionally, both EBNA2 mRNA and protein were expressed, although at significantly lower levels than those commonly observed in LCLs (Fig. 5) (51, 52, 53, 58) . The reduced expression of the LMP1 gene may contribute to the unusual cellular phenotype observed in the round B-cell lines, since it has been shown that this protein is specifically involved in the downregulation of CD10 and the upregulation of ICAM-1 and LFA-1 in transfection experiments of EBV-negative BL cell lines (51) .
While all the round B-cell lines appear to express normally spliced LMP2B transcripts, LMP2A transcripts could not be detected. LMP2A and LMP2B are not required for in vitro transformation of primary human B cells (21) . Instead, they appear to be involved in regulating the reactivation of the virus in vivo (24) . The lack of expression of LMP2A has not previously been observed in either B-cell or NPC cell systems (25) . Since this protein has recently been shown to associate with key components of the B-cell signaling pathway and to block the mobilization of calcium following immunoglobulin M receptor ligation (25) , the lack of expression of this protein in the round B-cell lines may have contributed to the establishment of their latency phenotype.
The expression of CD23 during latent infection of LCLs has been shown to be activated by both EBNA2 and LMP1. LMP1 specifically upregulates the activity of the CD23B promoter, whereas EBNA2 activates a regulatory element common to the CD23A and CD23B promoters (51, 52) . Since (3, 14, 44) . Latency II expression has also been experimentally induced in two B-cell models (16, 36 (Fig. 2 and 3 ) and EBNA2 is expressed, albeit at a low level (Fig. 5) .
It is becoming increasingly apparent that strictly defined latency states may not reflect the dynamic nature of the EBV-host interaction, as evidenced by the differential expression of latent gene products in various B-cell environments (16, 36, 37 
